NK cell-based immunotherapy for malignant diseases. - Wikidata - wikimedia - TriplyDB

NK cell-based immunotherapy for malignant diseases.

NK cell-based immunotherapy for malignant diseases.

http://www.wikidata.org/entity/Q33827433

about

CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas "Natural Regulators": NK Cells as Modulators of T Cell Immunity Immune Cells in Cancer Therapy and Drug Delivery The Sweet Side of Immune Evasion: Role of Glycans in the Mechanisms of Cancer Progression Cord Blood as a Source of Natural Killer Cells Liver natural killer cells: subsets and roles in liver immunity The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity Stem Cells and Regenerative Medicine: Myth or Reality of the 21th Century Strategies for combining immunotherapy with radiation for anticancer therapy Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy The Role of the Immune Response in Chlamydia trachomatis Infection of the Male Genital Tract: A Double-Edged Sword In vivo monitoring of natural killer cell trafficking during tumor immunotherapy Immunotherapy for colorectal cancer Genetically modified T cells in cancer therapy: opportunities and challenges 'Trained immunity': consequences for lymphoid malignancies PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations Induced pluripotent stem cells in dentistry Comprehensive assessment of cancer missense mutation clustering in protein structures Combining vasculature disrupting agent and Toll-like receptor 7/8 agonist for cancer therapy.Altered expression of miR-181a and miR-146a does not change the expression of surface NCRs in human NK cells.Low Dose Focused Ultrasound Induces Enhanced Tumor Accumulation of Natural Killer Cells.Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Activated Natural Killer Cells Mediate the Suppressive Effect of Interleukin-4 on Tumor Development via STAT6 Activation in an Atopic Condition Melanoma Model.Silencing NKG2D ligand-targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancer Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours.Cell-mediated delivery of nanoparticles: taking advantage of circulatory cells to target nanoparticles.Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective Ovarian tumor-associated microRNA-20a decreases natural killer cell cytotoxicity by downregulating MICA/B expression.Agonist antibody that induces human malignant cells to kill one another.Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells.Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities.Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.Lack of in vivo antibody dependent cellular cytotoxicity with antibody containing gold nanoparticles Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.Alloferon Alleviates Dextran Sulfate Sodium-induced Colitis Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain.Clinically applicable magnetic-labeling of natural killer cells for MRI of transcatheter delivery to liver tumors: preclinical validation for clinical translation.

P2860

Q26740520-D1F28AD7-43C1-4EC2-8A4C-307783FEDE7C Q26744551-A747C707-6AFB-4DC0-AEE5-83A69412B6D3 Q26747061-027ABD4B-F20D-4C75-8149-92AB260B781C Q26750877-322730BA-D4D0-4625-8F97-72B4D897B2DF Q26771337-DAB8CF48-163E-4707-B453-B8133EE81082 Q26774237-FEC166F1-A16B-457E-A69A-3C6F54B0CB99 Q26774678-E32504CD-01BA-40A5-8905-64CCE5E848D5 Q26782520-04E34EF9-E6FE-44E8-98AF-C860C7111E19 Q26795447-3C123C97-1FC1-4E41-B9B1-5D9717209173 Q26796675-FE6634C9-43CC-4B6B-94A5-0F2736A3CC5D Q26823515-4AFF4E57-C707-4A07-8ED3-D872B6F0AC79 Q26851537-B1FA933F-0704-47CF-AABB-1D78D4525A23 Q27011245-AA88F184-95C6-4784-A1E8-75A8BBD64F98 Q27021837-0D0D29DC-F561-42A5-8872-C65C145FE0B2 Q27026627-26757FC7-60F1-49A9-B96E-092A827F7786 Q28074639-FD187A60-30E7-4C05-9612-E448AC75FC25 Q28075712-64AC7DD3-775F-470C-B740-32108801365F Q28078372-0AEB2F1C-66A5-4831-99B5-AAD009879043 Q28606437-CB59267E-43BD-41D1-9D08-E481BC837520 Q30358185-72D2D729-EAEF-48E6-BBF7-DAAA400B9729 Q30364263-FB35CD1C-0AF1-44E2-A433-1FFC65EBB5A7 Q30398870-FC162EB1-14B0-4F21-932E-C9D62AB937D8 Q33741471-EC66095D-8C57-4A55-94EA-44BD7E7C889A Q33765161-F3C1A72C-8039-4DC0-AAAD-533716B71027 Q33815894-DF389E8D-079F-408D-851B-BA27923940CE Q33861833-01D5D053-2FB2-4395-94F9-1430C7D281B1 Q34079604-F3710EFB-5046-447C-969E-CD43F263A619 Q34180695-980B4DC1-BB31-4DD8-BDF6-4A7AB2D9E4A2 Q34339775-F9A23788-7741-4566-9C0B-39F1E328FA37 Q34498809-C533BC7D-F48F-48A7-87AA-7FC96AB8DBF7 Q34551199-42E1CFC4-5982-4139-AF6C-DA9DC248E517 Q34580297-79BB5DEF-ECCA-4A85-BEC9-FDE69F7B531A Q34765959-916CD6C8-FE11-411C-9147-76FA219F5E72 Q34786615-AE5B3283-985A-4A61-B60C-94EAEAE2A500 Q35600095-70926454-8141-4AA9-818E-5D97583F8768 Q35653952-A8785C7A-1D55-41A1-9700-C843AC2106FE Q35710332-AC7E8AF9-E3D0-4A29-9B3F-EEEBBC606E23 Q35802588-76960239-A784-4A1D-B38E-5B0A73304C11 Q35878535-6E875C24-04A1-4945-B215-17F573407A33 Q35903264-A90F4833-F9E1-4A90-AE0A-83C61B23A9EB

P2860

NK cell-based immunotherapy for malignant diseases.

http://www.wikidata.org/entity/Q33827433

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

NK cell-based immunotherapy for malignant diseases.

@ast

NK cell-based immunotherapy for malignant diseases.

@en

type

label

NK cell-based immunotherapy for malignant diseases.

@ast

NK cell-based immunotherapy for malignant diseases.

@en

prefLabel

NK cell-based immunotherapy for malignant diseases.

@ast

NK cell-based immunotherapy for malignant diseases.

@en

P1433

Q33827433-ADB8F91D-338C-46CD-AE8A-0A2F2DDA252C

P1476

Q33827433-829FE534-91C3-4459-A894-8FB99E80679D

P2093

Q33827433-50CEAD8F-DB34-486A-872B-5AA16A3E900A

Q33827433-5B0E9F57-07F8-454B-AF86-34A881BCE438

Q33827433-604EDA2A-1FF3-47D4-A932-79045544FFCE

Q33827433-DB66F416-AD2A-4A52-BAB7-27D4BBA6048A

Q33827433-E46406D5-496D-40B2-B9DC-7D2DB5217A66

P2860

Q33827433-014F1B54-6331-42D2-8608-E06D34FD788F

Q33827433-01CC0A88-2F6E-4957-947E-E27704F60AF0

Q33827433-023DC0DF-EE0E-489A-8A22-87E9B2CD5A42

Q33827433-04F9ECFB-F542-4519-ACD9-7CAEB6E9295D

Q33827433-06FCF602-4BEB-4ED8-BA0D-F84DA0F34E1A

Q33827433-0743E9E0-E138-45AB-ACB1-45F4641A8A08

Q33827433-08460F70-6EE9-46F1-8417-32CC6DB9C1FE

Q33827433-085A172D-2035-4A65-9307-40FFA172D847

Q33827433-08FE127A-2DE5-439B-A2D4-C5D73EAEA509

Q33827433-0AB3D430-2F42-46C7-8379-F200B3191889

P2888

Q33827433-0FCF87B7-C27B-4EE0-967D-EFFC1C35286F

P304

Q33827433-23EB3F72-BE87-4159-AB2F-BC0BF62ADCBA

P31

Q33827433-D0C97CC0-4FEC-4454-BD48-9C22C64C3EB1

P356

Q33827433-18FE55D9-DB7D-4522-8B40-E10E94204815

P433

Q33827433-547EBDA2-C772-41C1-A442-1EA8710AB0F8

P478

Q33827433-A69EB307-6E3A-4271-8D71-1667E2EE8985

P577

Q33827433-0FD583CD-F787-499F-9653-D9CCF70AE394

P5875

Q33827433-A61E9E89-BDA1-414B-9308-03B8AA8AC0C1

P6179

Q33827433-0B950E4A-2846-442A-85C1-8F4707872BC0

P698

Q33827433-84038F34-8575-4878-BC35-DB3817466D98

P921

Q33827433-E66BDD20-9016-46BB-AE85-259E7FBF31E3

P932

Q33827433-2DE759F1-8285-4EDE-B8F3-011406FCA017

P356

P1433

Cellular and Molecular Immunology

P1476

NK cell-based immunotherapy for malignant diseases.

@en

P2093

Min Cheng

http://www.w3.org/2001/XMLSchema#string

Rui Sun

http://www.w3.org/2001/XMLSchema#string

Weihua Xiao

http://www.w3.org/2001/XMLSchema#string

Yongyan Chen

http://www.w3.org/2001/XMLSchema#string

Zhigang Tian

http://www.w3.org/2001/XMLSchema#string

P2860

Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function

Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells

Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells

High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy

In search of the 'missing self': MHC molecules and NK cell recognition

IL-21 induces the functional maturation of murine NK cells

Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice

Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process

Cellular Immunotherapy of Malignancies Using the Clonal Natural Killer Cell Line NK-92

Functions of natural killer cells

P2888

P304

230-252

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CMI.2013.10

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236252692

http://www.w3.org/2001/XMLSchema#string

P6179

1021182766

http://www.w3.org/2001/XMLSchema#string

P698

23604045

http://www.w3.org/2001/XMLSchema#string

P921

P932

4076738

http://www.w3.org/2001/XMLSchema#string